Risk factors associated with myasthenia gravis in thymoma patients: The potential role of thymic germinal centers.


Journal

Journal of autoimmunity
ISSN: 1095-9157
Titre abrégé: J Autoimmun
Pays: England
ID NLM: 8812164

Informations de publication

Date de publication:
01 2020
Historique:
received: 12 08 2019
revised: 21 09 2019
accepted: 23 09 2019
pubmed: 9 10 2019
medline: 9 6 2021
entrez: 10 10 2019
Statut: ppublish

Résumé

Thymomas are associated with a very high risk of developing Myasthenia Gravis (MG). Our objectives were to identify histological and biological parameters to allow early diagnosis of thymoma patients susceptible to developing MG. We conducted a detailed retrospective analysis from a patient database, searching for differences between patients with thymoma-associated MG (MGT, n = 409) and thymoma without MG (TOMA, n = 111) in comparison with nonthymomatous MG patients (MG, n = 1246). We also performed multiplex and single molecule arrays to measure the serum levels of cytokines in these groups of patients and controls (n = 14-22). We identified a set of parameters associated with MG development in thymoma patients: 1) detection of anti-acetylcholine receptor (AChR) antibodies, 2) development of B1 or B2 thymoma subtypes, 3) presence of ectopic thymic germinal centers (GCs), 4) local invasiveness of thymoma, and 5) being a woman under 50 years old. Among these parameters, 58.8% of MGT patients displayed GCs with a positive correlation between the number of GCs and anti-AChR titers. By immunohistochemistry, we found thymic GCs in the adjacent tissues of thymomas encircled by high endothelial venules (HEVs) that could favor peripheral cell recruitment. We also clearly associated MG symptoms with higher IFN-γ, IL-1β and sCD40L serum levels, specifically in MGT patients compared to TOMA patients. Altogether, these analyses allowed the clear identification of histological, in particular the presence of GCs, and biological parameters that would facilitate the evaluation of the probability of the MG outcome postoperatively in thymoma patients.

Identifiants

pubmed: 31594658
pii: S0896-8411(19)30528-1
doi: 10.1016/j.jaut.2019.102337
pii:
doi:

Substances chimiques

Autoantibodies 0
Interleukin-1beta 0
Receptors, Cholinergic 0
CD40 Ligand 147205-72-9
Interferon-gamma 82115-62-6

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

102337

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Claire Mj Lefeuvre (CM)

Sorbonne University, INSERM, Association Institute of Myology, Center of Research in Myology, UMRS 974, Paris, France.

Cloé A Payet (CA)

Sorbonne University, INSERM, Association Institute of Myology, Center of Research in Myology, UMRS 974, Paris, France.

Odessa-Maud Fayet (OM)

Sorbonne University, INSERM, Association Institute of Myology, Center of Research in Myology, UMRS 974, Paris, France.

Solène Maillard (S)

Sorbonne University, INSERM, Association Institute of Myology, Center of Research in Myology, UMRS 974, Paris, France.

Frédérique Truffault (F)

Sorbonne University, INSERM, Association Institute of Myology, Center of Research in Myology, UMRS 974, Paris, France.

Vincent Bondet (V)

Immunobiology of Dendritic Cells, INSERM U1223, Institut Pasteur, Paris, France.

Darragh Duffy (D)

Immunobiology of Dendritic Cells, INSERM U1223, Institut Pasteur, Paris, France.

Vincent de Montpreville (V)

Department of Pathology, Marie Lannelongue Hospital, Paris-Sud University, Le Plessis-Robinson, France.

Maria-Rosa Ghigna (MR)

Department of Pathology, Marie Lannelongue Hospital, Paris-Sud University, Le Plessis-Robinson, France.

Elie Fadel (E)

Department of Pathology, Marie Lannelongue Hospital, Paris-Sud University, Le Plessis-Robinson, France.

Audrey Mansuet-Lupo (A)

Department of Pathology, Cochin University Hospital Group, AP-HP, Paris-Descartes University, Paris, France.

Marco Alifano (M)

Department of Pathology, Cochin University Hospital Group, AP-HP, Paris-Descartes University, Paris, France.

Pierre Validire (P)

Department of Pathology, Institut Mutualiste Montsouris, Paris, France.

Dominique Gossot (D)

Department of Pathology, Institut Mutualiste Montsouris, Paris, France.

Anthony Behin (A)

AP-HP, Referral Center for Neuromuscular Disorders, Institute of Myology, Pitié-Salpêtrière Hospital, Paris, France.

Bruno Eymard (B)

AP-HP, Referral Center for Neuromuscular Disorders, Institute of Myology, Pitié-Salpêtrière Hospital, Paris, France.

Sonia Berrih-Aknin (S)

Sorbonne University, INSERM, Association Institute of Myology, Center of Research in Myology, UMRS 974, Paris, France.

Rozen Le Panse (R)

Sorbonne University, INSERM, Association Institute of Myology, Center of Research in Myology, UMRS 974, Paris, France. Electronic address: rozen.lepanse@upmc.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH